AZD-8186 Active Not Recruiting Phase 1 Trials for Stage IIIC Prostate Cancer AJCC v8 / advanced carcinoma of the prostate / Castration-Resistant Prostate Carcinoma / Anatomic Stage IV Breast Cancer AJCC v8 / Stage IIIB Prostate Cancer AJCC v8 / Metastatic Breast Carcinoma / Stage IIIA Prostate Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Triple Negative Breast Carcinoma / Stage IVB Prostate Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / metastatic Malignant Solid Neoplasms / Advanced Breast Carcinoma / Unresectable Solid Tumor / Stage III Prostate Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Advanced Malignant Solid Tumor / Stage IV Prostate Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / metastatic Carcinoma of the Prostate / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03218826PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery